MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury


This potential treatment opportunity was confirmed by the company’s bioinformatics platform, PsyCollage

VANCOUVER, BC, March 4, 2021 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and ...

Continue Reading →

Missouri Bill Would Add Psychedelics to ‘Right to Try’ Law


Missouri Republican state Rep. Michael Davis last week introduced a measure to expand the state’s Right to Try statute to include Schedule I investigational drugs, including psilocybin, MDMA, LSD, mescaline, ibogaine, and DMT. The drugs would only be available after all other treatment options have been exhausted.

The Right to Try Law, enacted in the state in 2014, allows patients with terminal ...

Continue Reading →

Universal Ibogaine names Dr Rami Batal as the company’s new CEO


Universal Ibogaine Chairman Shayne Nyquvest joined Steve Darling from Proactive with news the company has named Dr. Rami Batal as their news CEO.

Nyquvest telling Proactive why they have put the company in Dr. Batal’s hands moving forward. Batal telling Proactive about his background his vision for the company and the path to the medicalization of ibogaine.


Source link

Continue Reading →
Page 1 of 50 12345...»